EMERYVILLE, Calif.–(BUSINESS WIRE)–Octant, Inc., a clinical-stage drug discovery company developing corrector therapies for protein misfolding diseases, today announced the appointment of Eddy Anglade, M.D., as its first Chief Medical Officer. Dr. Anglade will lead Octant’s clinical development strategy, including advancing its lead program, OCT-980 for rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP). “OCT-980 is the first molecule from our platform to reach patients,

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.